Epidermoid anal cancer prognosis comparison among HIV+ and HIV− patients

doi:10.1111/j.1365-2036.2009.04026.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

Alimentary Pharmacology & Therapeutics

Volume 30 Issue 4, Pages 414 - 421

Published Online: 17 Apr 2009

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | References | Full Text: HTML, PDF (Size: 157K) | Related Articles | Citation Tracking

Epidermoid anal cancer prognosis comparison among HIV+ and HIV− patients

L. ABRAMOWITZ*, N. MATHIEU*, F. ROUDOT-THORAVAL†, N. LEMARCHAND‡, P. BAUER§, C. HENNEQUIN¶, E. MITRY**, C. ROMELAER‡, T. APARICIO* & I. SOBHANI††

*AP-HP, Service de gastroentérologie et Unité de proctologie medico-chirurgicale, Hôpital Universitaire Bichat, Paris, France ; †AP-HP, Service de Santé Publique, Hôpital Henri Mondor, Université Paris, Créteil, France ; ‡Service de proctologie, hôpital Leopold Bellan, Paris, France ; §Service de proctologie medico-interventionnelle, Groupe Hôspitalier Diaconesse Croix Saint Simon, Paris, France ; ¶AP-HP, Service de radiothérapie, Hôpital universitaire Saint Louis, Paris, France ; **AP-HP, Service de gastroentérologie, Hôpital universitaire Ambroise Paré, Boulogne, France ; ††AP-HP, Université Paris 12, Service d'hépato-gastro-entérologie et oncologie; CHU Henri Mondor Créteil, Créteil, France

Correspondence to Dr L. Abramowitz, Service de Gastroentérologie et Proctologie, Hôpital Universitaire Bichat Claude Bernard, 46 rue Henri Huchard, 75877 Paris, CEDEX 18, France.
E-mail: laurent.abramowitz@bch.aphp.fr

ABSTRACT

Background Previous studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients.

Aim To investigate the long-term outcome of epidermoid anal cancer in HIV+ and HIV− patients in the highly active antiretroviral treatment (HAART) era.

Methods We included all patients with epidermoid anal cancer referred to six hospitals from 1998 to 2004.

Results In all, 151 patients (44 HIV+, 107 HIV−) were reviewed retrospectively for 27 (median of 16–44) months. HIV+ patients were male (100% vs. 27%, P < 0.001) and younger (45 vs. 62 years old, P < 0.001) than HIV− patients. No significant differences were observed in the tumour stage, pelvic radiotherapy dose or concomitant chemotherapy, according to the HIV status. After chemoradiotherapy, similar numbers of HIV+ and HIV− patients had grade III-IV toxicity. A complete response was obtained in 82% and 75% (N.S.) of cases, respectively. The disease-free survival rates were 77% and 67% (N.S.) and the overall survival rates were 85% and 84% (N.S.), respectively, after 3 years of follow-up. Duration of HIV infection, viral load and CD4 count had no effect on the survival rate of HIV+ patients with EAC.

Conclusions The clinical outcome of HIV+ patients with epidermoid anal cancer is similar to that of HIV− patients. Therefore, the same therapeutic guidelines should be applied to both populations.

Publication data Submitted 11 March 2009 First decision 27 March 2009 Resubmitted 14 April 2009 Accepted 14 April 2009 Epub Accepted Article 15 April 2009

DIGITAL OBJECT IDENTIFIER (DOI)

10.1111/j.1365-2036.2009.04026.x About DOI